Successful Treatment of Pediatric Refractory/Relapsed AML with KIR-Ligand-Mismatched Cord Blood Transplant after FLAG-IDA Reinduction Therapy with or without the GO Regimen

Prognosis in pediatric patients with refractory/relapsed acute myeloid leukemia (AML) is grim, and there is no standard treatment for such patients. Combined treatment with intensive chemotherapy and gemtuzumab ozogamicin (GO), a monoclonal anti-CD33 antibody conjugated with calicheamicin, is useful...

Descripción completa

Detalles Bibliográficos
Autores principales: Toyama, Daisuke, Matsuno, Ryosuke, Sugishita, Yumiko, Kaneko, Ryota, Okamoto, Naoko, Koganesawa, Masaya, Fujita, Sachio, Akiyama, Kosuke, Isoyama, Keiichi, Yamamoto, Shohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037524/
https://www.ncbi.nlm.nih.gov/pubmed/32099697
http://dx.doi.org/10.1155/2020/1378056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037524/
https://www.ncbi.nlm.nih.gov/pubmed/32099697
http://dx.doi.org/10.1155/2020/1378056

Ejemplares similares